Migraine headache recurrence: Relationship to clinical, pharmacological, and pharmacokinetic properties of triptans

Headache

Volumn 43, Issue 4, 2003, Pages 376-388

  Géraud, Gilles ^a   Keywood, Charlotte ^b   Senard, Jean Michel ^c  

^a CHU RANGUEIL   (France)

^b Minerva Pharmaceutical Consulting   (United Kingdom)

^c CHU PURPAN   (France)

Author keywords

5 HT1B receptor; 5 HT1D receptor; Binding affinity; Correlation; Headache; Migraine; Potency; Recurrence; Triptans

Indexed keywords

ALMOTRIPTAN; ELETRIPTAN; FROVATRIPTAN; NARATRIPTAN; RIZATRIPTAN; SEROTONIN 1B RECEPTOR; SEROTONIN 1D RECEPTOR; SUMATRIPTAN; ZOLMITRIPTAN;

ANALGESIA; ARTICLE; BINDING AFFINITY; CLINICAL TRIAL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENCY; DRUG RECEPTOR BINDING; HEADACHE; HUMAN; INCIDENCE; MIGRAINE; PATIENT SATISFACTION; PRIORITY JOURNAL; RECURRENT DISEASE; TREATMENT OUTCOME;

ANIMALS; HALF-LIFE; HUMANS; MIGRAINE DISORDERS; RECEPTOR, SEROTONIN, 5-HT1B; RECEPTOR, SEROTONIN, 5-HT1D; RECEPTORS, SEROTONIN; RECURRENCE; SEROTONIN AGONISTS;

EID: 0347367161     PISSN: 00178748     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-4610.2003.03073.x     Document Type: Article

References (39)

1. Lipton RB, Stewart WF, Simon D. Medical consultation for migraine: results from the American Migraine Study. Headache. 1998;38:210-217.
2. Forward SP, McGrath PJ, MacKinnon D, Brown TL, Swann J, Currie EL. Medication patterns of recurrent headache sufferers: a community study. Cephalalgia. 1998;18:146-151.
3. Lipton RB, Goadsby PJ, Sawyer JP, Blakeborough P, Stewart WF. Migraine diagnosis and assessment of disability. Rev Contemp Pharmacother. 2000;11: 63-73.
4. Visser WH, Jaspers NM, de Vriend RH, Ferrari MD. Risk factors for headache recurrence after sumatriptan: a study in 366 migraine patients. Cephalalgia. 1996;16:264-269.
5. Ferrari MD. How to assess and compare drugs in the management of migraine: success rates in terms of response and recurrence. Cephalalgia. 1999;19(suppl 23):2-8.
6. 1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet. 2001;358: 1668-1675.
7. 1D receptors. Br J Pharmacol. 1999;127:93P.
8. 1B/1D agonist for the treatment of acute migraine. Cephalalgia. 1997;17: 418.
9. Ryan R, Géraud G, Goldstein J, Cady C, Keywood C. The clinical efficacy of frovatriptan: placebo-controlled studies. Headache. 2002;42(suppl):S84-S92.
10. Goldstein J, Keywood C. A low dose-finding study with frovatriptan in the acute treatment of migraine. Headache. 2002;42:41-48.
11. Havanka H, Dahlof C, Pop PH, et al. Efficacy of naratriptan tablets in the acute treatment of migraine: a dose-ranging study. Naratriptan S2WB2004 Study Group. Clin Ther. 2000;22:970-980.
12. Klassen A, Elkind A, Asgharnejad M, Webster C, Laurenza A. Naratriptan is effective and well tolerated in the acute treatment of migraine: results of a double-blind, placebo-controlled, parallel group study. Headache. 1997;37:640-645.
13. Bates D, Winter P. Efficacy and tolerability of naratriptan tablets (0.1 mg-2.5 mg) in the acute treatment of migraine. Eur J Neurol. 1998;5:S48-S49.
14. Mathew NT, Asgharnejad M, Peykamian M, Laurenza A. Naratriptan is effective and well tolerated in the acute treatment of migraine. Neurology. 1997; 49:1485-1490.
15. Pryse-Phillips W (Eletriptan Steering Committee). Comparison of oral eletriptan (40-80 mg) and oral sumatriptan (50-100 mg) for the treatment of acute migraine: A randomised, placebo-controlled trial in sumatriptan-naive patients. Cephalalgia. 1999;19: 355.
16. Steiner TJ (Eletriptan Steering Committee). Efficacy, safety and tolerability of oral eletriptan (40 mg and 80 mg) in the acute treatment of migraine: results of a Phase III study. Cephalalgia. 1998;18:385.
17. Goadsby PJ, Ferrari MD, Olesen J, et al. for the Eletriptan Steering Committee. Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Neurology. 2000;54:156-163.
18. Reches A (Eletriptan Steering Committee). Comparison of the efficacy, safety and tolerability of oral eletriptan and Cafergot® for the acute treatment of migraine. Cephalalgia. 1999;19:355.
19. Eletriptan data on file, Pfizer, 1998.
20. Eletriptan data on file, Pfizer, 1998.
21. Visser WH, Terwindt GM, Reines SA, Jiang K, Lines CR, Ferrari MD, for the Dutch/US Rizatriptan Study Group. Rizatriptan vs sumatriptan in the acute treatment of migraine. A placebo-controlled dose-ranging study. Arch Neurol. 1996;53:1132-1137.
22. Gijsman H, Kramer MS, Sargent J, et al. Double-blind, placebo-controlled, dose-finding study of rizatriptan (MK-462) in the acute treatment of migraine. Cephalalgia. 1997;17:647-651.
23. Kramer MS, Matzura-Wolfe D, Polis A, et al. and the Rizatriptan Multiple Attack Study Group. A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks. Neurology. 1998;51:773-781.
24. Tfelt-Hansen P, Teall J, Rodriguez F, et al. on behalf of the Rizatriptan 030 Study Group. Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine. Headache. 1998; 38:748-755.
25. Goldstein J, Ryan R, Jiang K, et al. and the Rizatriptan Protocol 046 Study Group. Crossover comparison of rizatriptan 5 mg and 10 mg vs sumatriptan 25 mg and 50 mg in migraine. Headache. 1998;38:737-747.
26. Teall J, Tuchman M, Cutler N, et al. on behalf of the Rizatriptan 022 Study Group. Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence: a placebo-controlled, outpatient study. Headache. 1998;38:281-287.
27. Solomon GD, Cady RK, Klapper JA, Earl ND, Saper JR, Ramadan NM, on behalf of The 042 Clinical Trial Study Group. Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine. Neurology. 1997;49:1219-1225.
28. Rapoport AM, Ramadan NM, Adelman JU, et al. on behalf of The 017 Clinical Trial Study Group. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. Neurology. 1997;49: 1210-1218.
29. Ryan RE, Diamond S, Giammarco RA, Aurora SK, Reed RC, Fletcher PE. Efficacy of zolmitriptan at early time points for acute treatment of migraine and treatment of recurrence. CNS Drugs. 2000;13:215-226.
30. Fernández FJ, Cabarrocas X, Zayas JM, Ferrer P, Luria X, for and on behalf of the Almotriptan Dose Finding Study Group. Oral almotriptan in the treatment of migraine: a dose finding study. Cephalalgia. 1999;19:362.
31. 1B/1D agonist, compared with sumatriptan 100 mg. Headache. 1998; 38:377-378.
32. Robert M, Cabarrocas X, Fernandez FJ, Zayas JM, Ferrer P, for and on behalf of the Almotriptan Multiple Attacks Study Group. Efficacy and tolerability of oral almotriptan in the treatment of migraine. Cephalalgia. 1998;18:406.
33. Pfaffenrath V, Cunin G, Sjonell G, Prendergast S. Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine; defining the optimum doses of oral sumatriptan. Headache. 1998;38:184-190.
34. The Oral Sumatriptan International Multiple-Dose Study Group. Evaluation of a multiple-dose regimen of oral sumatriptan for the acute treatment of migraine. Eur Neurol. 1991;31:306-313.
35. Nappi G, Sicuteri F, Byrne M, Roncolato M, Zerbini O. Oral sumatriptan compared with placebo in the acute treatment of migraine. J Neurol. 1994;241:138-144.
36. Tfelt-Hansen P, Henry P, Mulder LJ, Scheldewaert RG, Schoenen J, Chazot G. The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared to oral sumatriptan for migraine. Lancet. 1995;346:923-926.
37. Weiller C, May A, Limmroth V, et al. Brain stem activation in spontaneous human migraine attacks. Nat Med. 1995;7:658-660.
38. 1D agonist, in patients with acute migraine. Cephalalgia. 2001;21:727-732.
39. Napier C, Stewart M, Melrose H, Hopkins B, McHarg A, Wallis R. Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors. Eur J Pharmacol. 1999;368:259-268.